Boothroyd diagnosed with Parkinson's
Former Watford manager Aidy Boothroyd has revealed he has Parkinson's disease.
The 54-year-old says he was diagnosed three years ago following a routine health check while manager of England under-21s.
Parkinson's disease is a progressive neurological disorder affecting the brain and nervous system.
"The news came as a massive shock to me," the former defender said in a statement released by the League Managers Association (LMA).
He added: "It has taken me time to feel ready to share my diagnosis, and I have found it difficult not being completely open with people.
"Personally, my passion and love for coaching is as strong as ever, I am focusing on keeping physically fit, which is key to slowing down the progression of Parkinson's.
"I am ready to start the next chapter in my life."
LMA chief executive Richard Bevan said: "Aidy has displayed incredible positivity, resolve and determination since his Parkinson's diagnosis three years ago.
"We care deeply for all our members, and Aidy's attitude since his diagnosis has been an inspiration to our entire team as we continue to support him and his family throughout this unexpected and challenging time."
Boothroyd managed Watford from 2005-2008, winning promotion to the Premier League in 2006 and reaching an FA Cup semi-final the following season.
He also managed Colchester United, Coventry City, Northampton Town and from 2014-2021 was in charge of various England's youth teams.
Most recently he managed Indian side Jamshedpur.
Parkinson's disease affects nearly 10 million people worldwide and more than 150,000 in the UK.
There is no cure and no treatment to slow or stop the disease, although therapies exist to help manage symptoms.
If you are affected by any of the issues raised in this story, support and advice is available via the BBC Action Line.
Listen to the latest Football Daily podcast
Get football news sent straight to your phone
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
US appeals court confirms patent validity of Acadia's Parkinson's drug
(Reuters) -Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, its drug for hallucinations and delusions associated with Parkinson's disease. The decision supports a December 2023 ruling from the U.S. District Court of Delaware, ensuring the patent remains protected in Acadia's legal battle against India-based drugmaker MSN Laboratories. The appeals court followed a precedent that says an earlier patent claim cannot be invalidated by a later one if they share the same priority date. "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for Nuplazid, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for Nuplazid 34 mg capsule formulation into 2038," said CEO Catherine Owen Adams. This decision comes after another favorable ruling for Acadia regarding its formulation patent for Nuplazid. The court supported Acadia's claims of infringement and validity in its legal case against Aurobindo Pharma and other companies. The U.S. FDA approved Nuplazid for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis in 2016.
Yahoo
17 hours ago
- Yahoo
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ('Jupiter' or the 'Company'), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia's debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary JOTROL™ micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space. 'The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,' said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. 'By building on the same proprietary technology platform that underpins our prescription drug development, we're delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.' A New Standard in Evidence-Based Supplementation Nugevia's first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL™, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL™ is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease. Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. 'We cracked the code on resveratrol's widely published issue with bioavailability, and now we're unlocking its potential beyond the clinic,' added Rosén. 'Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.' Strategic Synergy with Core Pipeline The Nugevia launch adds a new dimension to Jupiter's value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030. The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model. 'Nugevia represents more than a product launch—it's a strategic engine for growth,' said Rosén. 'By leveraging our core science in a consumer format, we're creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It's smart capital allocation with real scientific impact.' A digital press kit, including high-resolution product imagery and key brand information, is available at . About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website About JOTROL Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson's Disease. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@
New York Post
a day ago
- New York Post
Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments
This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson's disease with over 96% accuracy, offering a low-cost way to identify the neurodegenerative disorder far earlier than now. A pilot study in the journal Nature Chemical Engineering unveiled the device, which looks much like a regular pen. 3 A patient with PD using the diagnostic pen for a writing task. Nature Chemical Engineering It's able pick up on subtle motor dysfunctions before they're visible to the naked eye, all by analyzing how people write. So, how does this futuristic fountain pen work? The tip is made of a flexible silicone material infused with magnetic particles, and it writes using a special ferrofluid ink that contains nanomagnets. As someone writes, pressure from the hand deforms the tip, causing changes in magnetic fields that produce electrical signals — like a Morse code of motor function. Those signals are then analyzed to detect the difference between healthy and Parkinson's-affected motor patterns. In tests with 16 participants — including 3 with Parkinson's — the system nailed the diagnosis with 96.22% accuracy. Even more impressive? The pen worked whether people wrote on paper or in the air, meaning it doesn't even require a surface. 3 Nature Chemical Engineering Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. This diagnostic pen is portable, inexpensive and doesn't rely on a neurologist to interpret results, making it a promising option for remote screenings, home use or even telehealth checkups. 'Our development of the diagnostic pen represents a low-cost, widely disseminable and reliable technology with the potential to improve PD diagnostics across large populations and resource-limited areas,' the researchers wrote. With further validation in a larger population, the device could be used not just for early diagnosis, but for ongoing symptom tracking and personalized treatment monitoring. 3 Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. highwaystarz – This is just the latest innovation aimed at tackling Parkinson's disease, which affects more than 10 million people worldwide and has no known cure. A recent study found that psilocybin — the psychedelic compound that gave 'magic mushrooms' their trippy reputation in the 1960s — showed serious promise for improving mood and motor function in people with Parkinson's disease. Tavapadon — a new drug that mimics dopamine by targeting certain receptors — has also shown promise in clinical trials by reducing motor fluctuations and maintaining symptom control with fewer side effects than traditional therapies. Produodopa — a continuous infusion therapy first administered in the UK — was approved by the US Food and Drug Administration last fall. Innovative approaches targeting the psychological aspects of the disease have been successful as well — with tandem cycling proving to be especially popular. Some New Yorkers even find relief by playing pingpong.
